Endometrial Cancer study: HWK-007
Official title Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
ClinicalTrials.gov ID: NCT07444814
What this study is testing
What is HWK-007?
an investigational antibody‑drug conjugate being studied as a potential treatment for endometrial cancer and other solid tumors is designed to bind the protein PTK7 on cancer cells and deliver a cell‑killing payload directly to those cells
Also referred to as HWK-007 anti-PTK7 targeted ADC.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to learn whether HWK-007 is safe and shows any anti‑cancer activity in people whose tumors have the PTK7 protein.
- Who it's for
- Adults with advanced or metastatic solid tumors (such as endometrial, ovarian, or certain lung cancers) that test positive for PTK7.
- What's involved
- Participants receive HWK-007 by IV infusion on a regular schedule, undergo clinic visits for physical exams, blood tests, and imaging scans to monitor safety and tumor response.
- Time commitment
- The trial runs for several months, with screening, repeated treatment cycles every few weeks, and follow‑up visits after treatment ends.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- non-squamous EGFR-Wt NSCLC
- Endometrial carcinoma
- Platinum Resistant Ovarian Cancer
- Non-squamous EGFR-Wt NSCLC
- Additional tumor indications to be defined in a future amendment
You likely can't join if
- Individual with known or suspected uncontrolled central nervous system (CNS) metastases
- Individual with history of carcinomatous meningitis
- Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
- Individual with evidence of corneal keratopathy or history of cornea transplant
- Any serious unresolved toxicities from prior therapy
- Significant cardiovascular disease
See the full eligibility criteria
- non-squamous EGFR-Wt NSCLC
- Endometrial carcinoma
- Platinum Resistant Ovarian Cancer
- Non-squamous EGFR-Wt NSCLC
- Additional tumor indications to be defined in a future amendment
- Individual with known or suspected uncontrolled central nervous system (CNS) metastases
- Individual with history of carcinomatous meningitis
- Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
- Individual with evidence of corneal keratopathy or history of cornea transplant
- Any serious unresolved toxicities from prior therapy
- Significant cardiovascular disease
- Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)
- History of pneumonitis/interstitial lung disease
- Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention
The study team makes the final eligibility decision.
Where it is enrolling
- Little Rock, Arkansas, United States
- Peoria, Illinois, United States
- Grand Rapids, Michigan, United States
- Hackensack, New Jersey, United States
- Buffalo, New York, United States
- Cleveland, Ohio, United States
- Austin, Texas, United States
- Houston, Texas, United States
- San Antonio, Texas, United States
- Fairfax, Virginia, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Little Rock, Arkansas, United States; Peoria, Illinois, United States; Grand Rapids, Michigan, United States; Hackensack, New Jersey, United States; Buffalo, New York, United States; Cleveland, Ohio, United States and 4 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.